BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 24517288)

  • 1. Shyness discriminates between children with 22q11.2 deletion syndrome and Williams syndrome and predicts emergence of psychosis in 22q11.2 deletion syndrome.
    Schonherz Y; Davidov M; Knafo A; Zilkha H; Shoval G; Zalsman G; Frisch A; Weizman A; Gothelf D
    J Neurodev Disord; 2014 Feb; 6(1):3. PubMed ID: 24517288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of the neuropsychiatric and neurocognitive phenotype in two microdeletion syndromes: velocardiofacial (22q11.2 deletion) and Williams (7q11.23 deletion) syndromes.
    Zarchi O; Diamond A; Weinberger R; Abbott D; Carmel M; Frisch A; Michaelovsky E; Gruber R; Green T; Weizman A; Gothelf D
    Eur Psychiatry; 2014 May; 29(4):203-10. PubMed ID: 24054518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Negative subthreshold psychotic symptoms distinguish 22q11.2 deletion syndrome from other neurodevelopmental disorders: A two-site study.
    Mekori-Domachevsky E; Guri Y; Yi J; Weisman O; Calkins ME; Tang SX; Gross R; McDonald-McGinn DM; Emanuel BS; Zackai EH; Zalsman G; Weizman A; Gur RC; Gur RE; Gothelf D
    Schizophr Res; 2017 Oct; 188():42-49. PubMed ID: 28041919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing the broad socio-cognitive profile of youth with Williams syndrome and 22q11.2 deletion syndrome.
    Weisman O; Feldman R; Burg-Malki M; Keren M; Geva R; Diesendruck G; Gothelf D
    J Intellect Disabil Res; 2017 Dec; 61(12):1083-1093. PubMed ID: 28990288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cross-sectional analysis of the development of response inhibition in children with chromosome 22q11.2 deletion syndrome.
    Shapiro HM; Wong LM; Simon TJ
    Front Psychiatry; 2013; 4():81. PubMed ID: 23966958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated Proinflammatory Markers in 22q11.2 Deletion Syndrome Are Associated With Psychosis and Cognitive Deficits.
    Mekori-Domachevsky E; Taler M; Shoenfeld Y; Gurevich M; Sonis P; Weisman O; Weizman A; Gothelf D
    J Clin Psychiatry; 2017; 78(9):e1219-e1225. PubMed ID: 29141125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors and the evolution of psychosis in 22q11.2 deletion syndrome: a longitudinal 2-site study.
    Gothelf D; Schneider M; Green T; Debbané M; Frisch A; Glaser B; Zilkha H; Schaer M; Weizman A; Eliez S
    J Am Acad Child Adolesc Psychiatry; 2013 Nov; 52(11):1192-1203.e3. PubMed ID: 24157393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutrophils to lymphocytes ratio and psychosis in 22q11.2 deletion syndrome - Clinical and scientific implications.
    Mekori-Domachevsky E; Taler M; Weinberger R; Guri Y; Dar S; Shani S; Dekel I; Weizman A; Gothelf D
    Schizophr Res; 2021 May; 231():164-169. PubMed ID: 33866261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying patterns of anxiety and depression in children with chromosome 22q11.2 deletion syndrome: comorbidity predicts behavioral difficulties and impaired functional communications.
    Stephenson DD; Beaton EA; Weems CF; Angkustsiri K; Simon TJ
    Behav Brain Res; 2015 Jan; 276():190-8. PubMed ID: 24906195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood brain barrier permeability increases with age in individuals with 22q11.2 deletion syndrome.
    Taler M; Mekori-Domachevsky E; Vergaelen E; Claes S; Serur Y; Dar S; Levy-Shraga Y; Weizman A; Swillen A; Gothelf D
    World J Biol Psychiatry; 2022 Jul; 23(6):475-482. PubMed ID: 34854358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Dysconnectivity in Ventral Striatocortical Systems in 22q11.2 Deletion Syndrome.
    Tepper Á; Cuiza A; Alliende LM; Mena C; Ramirez-Mahaluf JP; Iruretagoyena B; Ornstein C; Fritsch R; Nachar R; González-Valderrama A; Undurraga J; Cruz JP; Tejos C; Fornito A; Repetto G; Crossley N
    Schizophr Bull; 2022 Mar; 48(2):485-494. PubMed ID: 34931688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attention Deficit Hyperactivity Disorder Symptoms and Psychosis in 22q11.2 Deletion Syndrome.
    Niarchou M; Calkins ME; Moore TM; Tang SX; McDonald-McGinn DM; Zackai EH; Emanuel BS; Gur RC; Gur RE
    Schizophr Bull; 2018 Jun; 44(4):824-833. PubMed ID: 29040797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An examination of the relationship of anxiety and intelligence to adaptive functioning in children with chromosome 22q11.2 deletion syndrome.
    Angkustsiri K; Leckliter I; Tartaglia N; Beaton EA; Enriquez J; Simon TJ
    J Dev Behav Pediatr; 2012; 33(9):713-20. PubMed ID: 23117596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attention deficit hyperactivity disorder symptoms as antecedents of later psychotic outcomes in 22q11.2 deletion syndrome.
    Niarchou M; Chawner SJRA; Fiksinski A; Vorstman JAS; Maeder J; Schneider M; Eliez S; Armando M; Pontillo M; Vicari S; McDonald-McGinn DM; Emanuel BS; Zackai EH; Bearden CE; Shashi V; Hooper SR; Owen MJ; Gur RE; Wray NR; van den Bree MBM; Thapar A;
    Schizophr Res; 2019 Feb; 204():320-325. PubMed ID: 30093352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cross-sectional study of the development of volitional control of spatial attention in children with chromosome 22q11.2 deletion syndrome.
    Shapiro HM; Takarae Y; Harvey DJ; Cabaral MH; Simon TJ
    J Neurodev Disord; 2012 Feb; 4(1):5. PubMed ID: 22958432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological effects of COMT haplotypes and psychosis risk in 22q11.2 deletion syndrome.
    Gothelf D; Law AJ; Frisch A; Chen J; Zarchi O; Michaelovsky E; Ren-Patterson R; Lipska BK; Carmel M; Kolachana B; Weizman A; Weinberger DR
    Biol Psychiatry; 2014 Mar; 75(5):406-13. PubMed ID: 23992923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developmental trajectories of brain structure in adolescents with 22q11.2 deletion syndrome: a longitudinal study.
    Gothelf D; Penniman L; Gu E; Eliez S; Reiss AL
    Schizophr Res; 2007 Nov; 96(1-3):72-81. PubMed ID: 17804201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulant treatment effectiveness, safety and risk for psychosis in individuals with 22q11.2 deletion syndrome.
    Basel D; Mosheva M; Maeder J; Schneider M; Shani S; Weinberger R; Eliez S; Gothelf D
    Eur Child Adolesc Psychiatry; 2022 Sep; 31(9):1367-1375. PubMed ID: 33871687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying neurodevelopmental anomalies of white matter microstructure associated with high risk for psychosis in 22q11.2DS.
    Bagautdinova J; Padula MC; Zöller D; Sandini C; Schneider M; Schaer M; Eliez S
    Transl Psychiatry; 2020 Nov; 10(1):408. PubMed ID: 33235187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between oxidative stress and psychotic disorders in 22q11.2 deletion syndrome.
    Matalon N; Vergaelen E; Shani S; Dar S; Mekori-Domachevsky E; Segal-Gavish H; Hochberg Y; Gothelf D; Swillen A; Taler M
    Brain Behav Immun; 2023 Nov; 114():16-21. PubMed ID: 37541396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.